Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | DUT | P33316 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851745 | 0.97 | RECQL (0.55) | GAARECQLTDP1ALDH1A1DUT | |
| SCHEMBL9544542 | 0.91 | GAA (0.58) | GAARECQLTDP1ALDH1A1DUT | |
| SCHEMBL31712151 | 0.87 | GAA (0.67) | GAARECQLTDP1ALDH1A1DUT | |
| SCHEMBL14057890 | 0.85 | GAA (0.48) | GAARECQLTDP1ALDH1A1DUT | |
| SCHEMBL17493276 | 0.83 | MAPT (0.50) | TDP1ALDH1A1DUTMEN1KMT2A | |
| SCHEMBL4862778 | 0.82 | RECQL (0.48) | GAARECQLTDP1ALDH1A1MEN1 | |
| SCHEMBL17743343 | 0.82 | TDP1 (0.49) | TDP1DUTMEN1KMT2AMAPT | |
| SCHEMBL4119825 | 0.81 | MAPT (0.55) | DUTMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL24507059 | 0.79 | GAA (0.71) | GAARECQLTDP1ALDH1A1MEN1 | |
| SCHEMBL17641579 | 0.79 | GAA (0.43) | GAARECQLTDP1ALDH1A1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252595-B1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20120264770-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| US-8071766-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-06 | — | — | US | disclosed |
| US-8071766-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-06 | — | — | US | disclosed |
| US-20110053873-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305998-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | GAA 221/4885RECQL 442/4885TDP1 959/4885 |
| US-20120264770-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | GAA 221/4885RECQL 442/4885TDP1 959/4885 |
| US-20110053873-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | GAA 284/4885RECQL 412/4885TDP1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.